Diabetes Obes Metab 25(9):27842788 Jones PM, Hobai IA, Murphy PM (2023) Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution
Role and mechanism of specialized pro-resolving mediators in obesity-associated insulin resistance
While clinical use is still evolving, exosomes may eventually offer a powerful regenerative option. Additionally, the use of platelet-rich plasma (PRP) has emerged as a biostimulatory treatment in facial rejuvenation
Phase 2 trials demonstrated the practical importance of glucagon receptor activation
Retatrutide, Lillys follow-on molecule, is a triple agonist that adds the glucagon receptor to the same dual backbone and, in its first Phase 3 readout, produced the deepest weight reduction ever reported in a registrational obesity trial: about 28.7% at 68 weeks 5 vs tirzepatides SURMOUNT-1 peak of roughly 22.5% at 72 weeks 13